AeroVanc: Completed Phase II enrollment

Savara completed enrollment of 80 patients with CF in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 32 and 64 mg inhaled AeroVanc twice daily for 28 days. AeroVanc has Qualified I...